Array Biopharma Inc
$3.1M 8,513 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
BioFire Diagnostics, LLC
BioFire Diagnostics, LLC reported $3,067,163.01 across General Payments, Research, and Ownership to 11 physicians and teaching hospitals across 300 transactions.
- $3.1M Top quartile payer
- All-tracks total
- 300 Above-median volume
- Transactions
- 11 Below-median reach
- Recipients
- −$198.5K
- General Payments vs PY2023
BioFire Diagnostics, LLC reported $3,067,163.01 across all CMS Open Payments tracks (General + Research + Ownership) to 11 physicians and teaching hospitals in Program Year 2024 - ranking #358 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $2,594.95, averaging $278.8K per recipient.
How BioFire Diagnostics, LLC's $3.1M all-tracks total breaks down
BioFire Diagnostics, LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
21/100
Total payments
F
38/100
Transaction volume
F
12/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer biofire-diagnostics-llc BioFire Diagnostics, LLC
$3.1M · #358/1,925 · 0.0% industry · PY2024
- TOT $3.1M
- RANK #358
- SHARE 0.0%
- TXN 300
- RCP 11
- CAT 2
- GEN $2.6K
- ΔGEN −$198.5K
- TOP1 45.5%
- PY 2024
Volume peers
Nearest volume peer: Array Biopharma Inc ($3.1M)
BioFire Diagnostics, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
BioFire Diagnostics, LLC's CMS-reported General Payments decreased by $198.5K (−98.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: BIOFIRE DIAGNOSTICS, LLCPY2023: BIOFIRE DIAGNOSTICS, LLCPY2024: BioFire Diagnostics, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $201,095.40
- PY2024
- $2,594.95
What the Data Shows for BioFire Diagnostics, LLC
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For BioFire Diagnostics, LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Consulting Fee" leads the 2-category general-payment breakdown below at $2.0K (78.2% of General Payments, 3 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Consulting Fee" leads BioFire Diagnostics, LLC's 2-category general-payment breakdown at $2.0K, 78.2% of the reported total.
How BioFire Diagnostics, LLC divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $2.0K | 3 | 78.2% |
| Food and Beverage | $564.95 | 8 | 21.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $2,484.67 (95.8%) of $2,594.95 in this company's General Payments records across 9 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for BioFire Diagnostics, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Christina Muzny
$1,180.00 across 2 reported transactions
- 2
Jeffrey Klausner
$850.00 across 1 reported transactions
- 3
Larissa May
$300.25 across 2 reported transactions
- 4
Kevin Messacar
$105.42 across 1 reported transactions
- 5
Ferric Fang
$49.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
BioFire Diagnostics, LLC's spend rank (#358 of 1,925, top 19% by spend) and concentration rank (#532 of 1,838, top 29% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- OrganOx Ltd : $271.0K total payments, HHI 3335
- Midwest Surgical Alliance, LLC : $994.3K total payments, HHI 3333
- Uc-Care (usa), Inc : $12.9K total payments, HHI 3333
- Bioprotect Ltd. : $12.0K total payments, HHI 3333
- Cardinal Health 414 LLC : $311.8K total payments, HHI 3320
- Ortho Organizers, Inc. : $318.5K total payments, HHI 3318
- BioFire Diagnostics, LLC (this company) : $2.6K total payments, HHI 3299
- Menarini Silicon Biosystems, Inc. : $251.9K total payments, HHI 3287
- Grace Medical, Inc. : $46.8K total payments, HHI 3285
- Secura Bio, Inc. : $95.6K total payments, HHI 3279
- BeiGene, Ltd. : $222.0K total payments, HHI 3277
- Axis Spine Technologies Inc. : $26.4K total payments, HHI 3274
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as BioFire Diagnostics, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about BioFire Diagnostics, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with BioFire Diagnostics, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
NeuraMedica Inc.
$3.1M 0 recipients
Compare payment profiles
Visby Medical, Inc.
$3.0M 30 recipients
Compare payment profiles
Amneal Pharmaceuticals LLC
$3.1M 20,418 recipients
Compare payment profiles
MicroPort Orthopedics Inc
$3.0M 1,014 recipients
Compare payment profiles
Organogenesis Inc.
$3.1M 24,238 recipients
Compare payment profiles
Put this to use
BioFire Diagnostics, LLC ranks #358 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where BioFire Diagnostics, LLC sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just BioFire Diagnostics, LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.